Despite progress in antiplatelet, anticoagulant therapy and invasive strategy, patients with non-ST-segment elevation acute coronary syndrome present...

solaci - 24 June, 2015

Day 2

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes....

solaci - 24 June, 2015

Day 3

Group Tour of France: good news for cyclists.

The benefits of regular physical activity are well established, but there are some controversies related to the...

solaci - 24 June, 2015

Day 3

BIC 8: Copetin associated with troponin can rule out acute myocardial infarction in the emergency room.

The acute chest pain is responsible for more than 11 % of queries to an emergency service...

solaci - 24 June, 2015

Day 3

AQUARIUS: Aliskiren, without impact on the progression of atherosclerosis

This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and...

solaci - 24 June, 2015

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 21 November, 2024 0

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 20 November, 2024 0

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 19 November, 2024 0

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad

ESC 2013 .

ACCOAST: Pretreatment with prasugrel showed no benefits and increased bleeding in patients with non-ST segment myocardial infarction.

RE-ALIGN: Dabigatran in mechanical valves. Suspended early due to more bleeding and thrombotic events.

TASTE: Thrombus aspiration in primary angioplasty failed to show benefits at 30 days

TAO trial: Otamixaban without advantages as the only anticoagulant in acute coronary syndromes

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

Group Tour of France: good news for cyclists.

BIC 8: Copetin associated with troponin can rule out acute myocardial infarction in the emergency room.

AQUARIUS: Aliskiren, without impact on the progression of atherosclerosis

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

The El Salvador 2024 Sessions are coming soon

Check out the best images of the Arequipa 2024 Sessions

Accesos